Mitochondrial-targeting and NIR-responsive Mn₃O₄@PDA@Pd-SS31 nanozymes reduce oxidative stress and reverse mitochondrial dysfunction to alleviate osteoarthritis.

Li Y, Yang J, Chen X, Hu H, Lan N, Zhao J, Zheng L

Biomaterials22 Dec 2023Cited by 59 (Europe PMC)

PMID38194734DOI10.1016/j.biomaterials.2023.122449PepBankPUB-38194734

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In osteoarthritis joints in vivo, the Mn3O4@PDA@Pd-SS31 nanozymes reduced the inflammatory response.
In plain wordsIn animals with osteoarthritis, the SS31-containing nanoparticles reduced joint inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory response in OA joints
Study
n: not reported in source
Osteoarthritis joints
Outcome group
Inflammation markers · Musculoskeletal
Source sentences
Summary
effectively reducing the inflammatory response
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473407
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In osteoarthritis joints in vivo, the Mn3O4@PDA@Pd-SS31 nanozymes relieved cartilage degeneration, with a 93.7 % reduction in OARSCI score at 4 weeks.
In plain wordsIn animals with osteoarthritis, the SS31-containing nanoparticles reduced cartilage damage scores by 93.7 % at 4 weeks.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOARSCI score reduction at 4 weeks
Study
n: not reported in source
Osteoarthritis joints
Outcome group
Bone and joint · Musculoskeletal
Measurements
OARSCI score reduction
93.7%
4 weeks
Source sentences
Summary
relieving articular cartilage degeneration in OA joints, with a reduction of 93.7 % and 93.8 % in OARSCI scores for 4 and 8 weeks respectively.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473408
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In osteoarthritis joints in vivo, the Mn3O4@PDA@Pd-SS31 nanozymes relieved cartilage degeneration, with a 93.8 % reduction in OARSCI score at 8 weeks.
In plain wordsIn animals with osteoarthritis, the SS31-containing nanoparticles reduced cartilage damage scores by 93.8 % at 8 weeks.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOARSCI score reduction at 8 weeks
Study
n: not reported in source
Osteoarthritis joints
Outcome group
Bone and joint · Musculoskeletal
Measurements
OARSCI score reduction
93.8%
8 weeks
Source sentences
Summary
relieving articular cartilage degeneration in OA joints, with a reduction of 93.7 % and 93.8 % in OARSCI scores for 4 and 8 weeks respectively.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473409
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
The Mn3O4@PDA@Pd-SS31 nanozymes were excreted in vivo through the intestinal metabolic pathway.
In plain wordsIn animals, the SS31-containing nanoparticles left the body through the gut.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableExcretion of nanozymes
Study
n: not reported in source
In vivo
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Nanozymes were excreted in vivo through intestinal metabolic pathway
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473410
05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome
The Mn3O4@PDA@Pd-SS31 nanozymes had good biocompatibility in vivo.
In plain wordsIn animals, the SS31-containing nanoparticles were well tolerated by the body.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableBiocompatibility of nanozymes
Study
n: not reported in source
In vivo
Outcome group
Adverse events · Pharmacology
Source sentences
Summary
had good biocompatibility
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473411
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In chondrocytes, the Mn3O4@PDA@Pd-SS31 nanozymes reversed mitochondrial dysfunction.
In plain wordsIn cells, the SS31-containing nanoparticles reversed mitochondrial damage in cartilage cells.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMitochondrial dysfunction
Study
n: not reported in source
Mn3O4@PDA@Pd-SS31 nanozymes in chondrocytes
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
with reversed mitochondrial dysfunction
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473403
07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In chondrocytes, the Mn3O4@PDA@Pd-SS31 nanozymes promoted mitophagy.
In plain wordsIn cells, the SS31-containing nanoparticles increased the clearing of damaged mitochondria in cartilage cells.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitophagy
Study
n: not reported in source
Mn3O4@PDA@Pd-SS31 nanozymes in chondrocytes
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
promoted mitophagy
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473404
08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
The Mn3O4@PDA@Pd-SS31 nanozymes effectively scavenged mitochondrial ROS from chondrocytes.
In plain wordsIn cells, the SS31-containing nanoparticles removed harmful reactive oxygen molecules from cartilage-cell mitochondria.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMitochondrial ROS in chondrocytes
Study
n: not reported in source
Mn3O4@PDA@Pd-SS31 nanozymes in chondrocytes
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
effectively scavenge mROS from chondrocytes
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473405
09LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
In chondrocytes, the Mn3O4@PDA@Pd-SS31 nanozymes inhibited the inflammatory response.
In plain wordsIn cells, the SS31-containing nanoparticles reduced inflammation in cartilage cells.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory response in chondrocytes
Study
n: not reported in source
Mn3O4@PDA@Pd-SS31 nanozymes in chondrocytes
Outcome group
Inflammation markers · Musculoskeletal
Source sentences
Summary
eventually inhibit the inflammatory response
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473406
10LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Activity measurement
The Mn3O4@PDA@Pd-SS31 nanozymes accelerated the release of Pd and Mn3O4 under NIR irradiation.
In plain wordsIn lab tests, near-infrared light made the SS31-containing nanoparticles release their metal components faster.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRelease of Pd and Mn3O4 under NIR
Study
n: not reported in source
Nanozyme under NIR irradiation
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
accelerated the release of Pd and Mn₃O₄ under NIR irradiation
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473401
11LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Activity measurement
The Mn3O4@PDA@Pd-SS31 nanozymes exhibited enhanced SOD and CAT mimic enzyme activities.
In plain wordsIn lab tests, the SS31-containing nanoparticles showed stronger antioxidant enzyme-like activity.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseSOD and CAT mimic enzyme activity
Study
n: not reported in source
Nanozyme under NIR irradiation
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
exhibiting enhanced activities of SOD and CAT mimic enzymes
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, novel mitochondrial-targeting and SOD-mimic Mn₃O₄@PDA@Pd-SS31 nanozymes with near-infrared (NIR) responsiveness and synergistic cascade to scavenge mROS were designed for the therapy of OA.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3819473402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.